©2025 Bryn Mawr Communications, LLC.
All Rights Reserved

Terms and Conditions • Privacy Policy
Art of Drug Choice Header Bar

Editorial Feature:

The Art of Drug Choice

Wet AMD and the Latest Data

Editorially Independent content supported with advertising by Novartis and Alcon.

The Value of Treatment Options in Wet AMD

Justus G. Garweg, MD

Show Description +

Justus G. Garweg, MD (Switzerland), reviews the case of a man whose wet AMD stopped responding to the only anti-VEGF available at the time, ranibizumab (Lucentis, Genentech). The patient was moved to aflibercept (Eylea, Regeneron) as soon as it was approved for use. How did this switch affect his outcomes?

Posted: 8/05/2021

Keywords:

Wet AMD

•

Anti-VEGF

•

Ranibizumab

•

aflibercept

Up Next

Switching to a New Anti-VEGF Agent Early in the Course of Therapy
Switching to a New Anti-VEGF Agent Early in the Course of Therapy

Seenu M. Hariprasad, MD

Extending Duration in a Patient With Polypoidal Choroidal Vasculopathy
Extending Duration in a Patient With Polypoidal Choroidal Vasculopathy

Peter Kertes, MD, FRCS(C)

Managing a Patient With High Treatment Burden and a History of Intraocular Inflammation
Managing a Patient With High Treatment Burden and a History of Intraocular Inflammation

Arshad M. Khanani, MD, MA

Management of IOI After Anti-VEGF Therapy in a 12-year Wet AMD Patient
Management of IOI After Anti-VEGF Therapy in a 12-year Wet AMD Patient

Arshad M. Khanani, MD, MA

Switching Agents Multiple Times in a Long-term Wet AMD Patient
Switching Agents Multiple Times in a Long-term Wet AMD Patient

Lejla Vajzovic, MD

Extending Treatment Intervals in a 90-Year-Old Wet AMD Patient
Extending Treatment Intervals in a 90-Year-Old Wet AMD Patient

Joseph M. Coney, MD

Increasing Treatment Intervals in Wet AMD
Increasing Treatment Intervals in Wet AMD

Arshad M. Khanani, MD

A Breakthrough After Monthly Wet AMD Therapy
A Breakthrough After Monthly Wet AMD Therapy

Nikolas J.S. London, MD

Navigating Treatment Burden in Wet AMD
Navigating Treatment Burden in Wet AMD

Christina Weng, MD, MBA

Outside-the-Box Therapy for Wet AMD
Outside-the-Box Therapy for Wet AMD

Christopher G. Fuller, MD

link-arrow   Back to All Videos

The Value of Treatment Options in Wet AMD

Justus G. Garweg, MD

Justus G. Garweg, MD (Switzerland), reviews the case of a man whose wet AMD stopped responding to the only anti-VEGF available at the time, ranibizumab (Lucentis, Genentech). The patient was moved to aflibercept (Eylea, Regeneron) as soon as it was approved for use. How did this switch affect his outcomes?

Posted: 8/05/2021

Keywords:

Wet AMD

•

Anti-VEGF

•

Ranibizumab

•

aflibercept

Please log in to leave a comment.

Listen as a Podcast

nrr podcast logo

New Retina Radio

All video episodes of this series are also available as podcast episodes on New Retina Radio.

Listen Now

close-x